p-Tau217 Adaptive Dosing Protocol

Migration, Crosslink

📖

p-Tau217 Adaptive Dosing Protocol

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ptau217-adaptive-dosin

📖 Wiki Page

therapeutic1570 wordssynced 2026-04-02

p-Tau217 Adaptive Dosing Protocol for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">p-Tau217 Adaptive Dosing Protocol</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Platform</td>
</tr>
<tr>
<td class="label">Palmqvist et al. 2020</td>
<td>Lumipulse</td>
</tr>
<tr>
<td class="label">Barthélemy et al. 2022</td>
<td>Simoa</td>
</tr>
<tr>
<td class="label">Smith et al. 2023</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Role</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Primary - tau pathology burden</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>Secondary - tau staging</td>
</tr>
<tr>
<td class="label">[NfL](/biomarkers/neurofilament-light-chain-nfl)</td>
<td>Safety - neurodegeneration gate</td>
</tr>
<tr>
<td class="label">[GFAP](/entities/gfap)</td>
<td>Secondary - astrocyte reactivity</td>
</tr>
<tr>
<td class="label">Aβ42/40 ratio</td>
<td>Secondary - amyloid status</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Metric</td>
</tr>
<tr>
<td class="label">Assay validation</td>
<td>Inter-lab CV</td>
</tr>
<tr>
<td class="label">Algorithm accuracy</td>
<td>AUC for progression</td>
</tr>
<tr>
<td class="label">Regulatory alignment</td>
<td>IND cleared</td>
</tr>
<tr>
<td class="label">Phase 2 readout</td>
<td>p-tau217 reduction</td>
</tr>
</table>

Overview

...

p-Tau217 Adaptive Dosing Protocol for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">p-Tau217 Adaptive Dosing Protocol</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Platform</td>
</tr>
<tr>
<td class="label">Palmqvist et al. 2020</td>
<td>Lumipulse</td>
</tr>
<tr>
<td class="label">Barthélemy et al. 2022</td>
<td>Simoa</td>
</tr>
<tr>
<td class="label">Smith et al. 2023</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Role</td>
</tr>
<tr>
<td class="label">p-tau217</td>
<td>Primary - tau pathology burden</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>Secondary - tau staging</td>
</tr>
<tr>
<td class="label">[NfL](/biomarkers/neurofilament-light-chain-nfl)</td>
<td>Safety - neurodegeneration gate</td>
</tr>
<tr>
<td class="label">[GFAP](/entities/gfap)</td>
<td>Secondary - astrocyte reactivity</td>
</tr>
<tr>
<td class="label">Aβ42/40 ratio</td>
<td>Secondary - amyloid status</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Metric</td>
</tr>
<tr>
<td class="label">Assay validation</td>
<td>Inter-lab CV</td>
</tr>
<tr>
<td class="label">Algorithm accuracy</td>
<td>AUC for progression</td>
</tr>
<tr>
<td class="label">Regulatory alignment</td>
<td>IND cleared</td>
</tr>
<tr>
<td class="label">Phase 2 readout</td>
<td>p-tau217 reduction</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

[p-Tau217](/biomarkers/p-tau-217) Adaptive Dosing Protocol is a biomarker-guided therapeutic approach that uses longitudinal measurements of phosphorylated tau 217 (p-tau217) as the primary biomarker for dose titration in Alzheimer's disease (AD), frontotemporal dementia (FTD), and related neurodegenerative conditions. Rather than fixed-dose regimens, this approach treats p-tau217 as a dynamic surrogate for tau pathology burden and adjusts dosing accordingly.[@palmqvist2020][@barthlemy2022]

p-Tau217 is one of the most promising fluid biomarkers for tau pathology, showing strong correlation with Braak staging and clinical progression in Alzheimer's disease.[@mattssoncarlgren2023][@smith2023] Unlike static biomarkers, p-tau217 responds rapidly to pathological changes, making it ideal for adaptive therapeutic dosing.[@janelidze2021][@hansson2022]

Biological Rationale

p-Tau217 as Tau Pathology Marker

p-Tau217 is a phosphorylated form of the [tau protein](/proteins/tau) that is highly specific to Alzheimer's disease pathology:

AD-specific: Strong correlation with amyloid and tau PET burden
Braak staging: Tracks progression through Braak stages I-VI
Clinical correlation: Predicts cognitive decline and disease progression
Dynamic range: Shows significant changes in response to disease progression and treatment[@mattssoncarlgren2023][@smith2023][@chen2023]

Mechanism of Action

The adaptive dosing protocol operates on a three-tier system:

Loading Phase: Initial intensive treatment targeting rapid tau clearance

Maintenance Phase: Dose titration based on p-tau217 trajectory

Escalation/De-escalation: Dynamic adjustment responding to biomarker trends

Clinical Evidence

Diagnostic Accuracy

Multiple studies have validated p-tau217 for AD diagnosis:

Longitudinal Trajectory Studies

Preclinical AD: p-tau217 elevated even before objective cognitive impairment[@smith2023][@milalom2023]
MCI-AD: p-tau217 trajectory predicts progression to dementia[@janelidze2021]
Treatment response: Changes in p-tau217 correlate with clinical outcomes[@hansson2022][@karikari2022]

Platform Comparison

Multiple analytical platforms quantify p-tau217 in plasma with high sensitivity:

Lumipulse (Fujirebio): FDA-cleared, automated immunoassay
Simoa (Quanterix): Ultra-sensitive research platform
Mass spectrometry: Precise, antibody-independent quantification
ALZpath: Reference standard for assay calibration[@thijssen2021][@cullen2023]

Adaptive Dosing Algorithm

Tier 1: Loading Phase

High-intensity intervention with tau aggregation inhibitors or anti-tau immunotherapies
Target: Achieve 30%+ reduction in p-tau217 within 12 weeks
Dosing: 2-3x maintenance dose
Duration: 12-24 weeks

Tier 2: Maintenance Phase

Quarterly p-tau217 monitoring
Dose adjustment algorithm:
p-tau217 declining >20%/quarter → maintain current dose
p-tau217 stable (within ±10%) → increase dose by 25%
p-tau217 rising >10% → escalate dose or add combination partner

Tier 3: Adaptive Response

Real-time biomarker integration with clinical endpoints
Machine learning model predicting optimal dosing windows
Integration with [amyloid-beta](/proteins/amyloid-beta) 42/40 ratio for comprehensive pathology tracking

Clinical Trial Design

Phase 1: Biomarker Validation

Study design: Single-arm study in 30 participants with MCI-AD
Primary endpoint: p-tau217 reproducibility across 3 timepoints
Secondary endpoints: Correlation with PET tau imaging, safety monitoring

Phase 2: Dose-Finding

Study design: Randomized, placebo-controlled in 150 participants
Primary endpoint: p-tau217 change at 52 weeks
Key features: Biomarker-driven dose escalation protocol, adaptive sample size

Phase 3: Registrational

Study design: Adaptive design with Bayesian interim analysis
Dual primary endpoints: Clinical (ADAS-Cog13) + biomarker (p-tau217)
Enrichment strategy: Based on baseline p-tau217 levels

Biomarker Panel

Regulatory Pathway

FDA Qualification

Status: p-tau217 is currently under FDA qualification review for AD diagnosis
Biomarker category: Susceptibility/Risk biomarker, Monitoring biomarker
Potential indication: Patient selection and treatment response monitoring

Surrogate Endpoint Considerations

Validation status: p-tau217 as surrogate endpoint is under investigation
Evidence needed: Correlational studies showing p-tau217 → clinical outcome relationship
Regulatory precedent: Similar to amyloid PET for accelerated approval

Therapeutic Applications

Alzheimer's Disease

Primary indication with strongest evidence:

Preclinical AD: Early intervention with biomarker-guided timing
MCI-AD: Optimal treatment initiation point
Mild-to-moderate AD: Adaptive dosing for disease modification

Frontotemporal Dementia

Secondary application in specific subtypes:

CBD/PSP: AD co-pathology detection
bvFTD: Differential diagnosis from AD
Primary Progressive Aphasia: Biomarker stratification

Other Indications

Primary Age-Related Tauopathy (PART): Exploratory
Down syndrome AD: Early detection
Mixed pathology: Biomarker triangulation

Combination Potential

This biomarker-driven approach synergizes with:

Tau-PROTAC heterobifunctional degraders: Complementary clearance mechanisms
Anti-amyloid immunotherapies ([Lecanemab](/entities/lecanemab), Donanemab): Upstream pathology reduction
[NLRP3 inflammasome](/entities/nlrp3-inflammasome) inhibitors: Neuroinflammation modulation
[TREM2](/proteins/trem2) agonists: Microglial modulation

Challenges and Considerations

Analytical Challenges

Platform variability: Inter-platform differences in absolute values and cutoffs
Pre-analytical factors: Sample handling, fasting status, diurnal variation
Standardization: Need for reference standards across platforms

Clinical Implementation

Cost: Ultra-sensitive assays remain expensive
Access: Limited availability outside specialized centers
Interpretation: Requires expertise in biomarker-guided decision making

Regulatory Hurdles

Surrogate endpoint validation: Long-term outcome data needed
Combination therapy trials: Complex regulatory requirements
Companion diagnostic: Co-development considerations

Actionable Next Steps

Immediate (0-6 months)

Assay Selection: Finalize p-tau217 assay platform (Lumipulse for clinical trials, Simoa for research). Establish central lab network with standardized protocols.

Retrospective Analysis: Mine existing AD cohort data (e.g., ALZheimer's Disease Neuroimaging Initiative, BioFINDER) for p-tau217 trajectory patterns to refine the 20% quarterly decline threshold.

Regulatory Pre-IND Meeting: Schedule FDA pre-IND meeting to discuss biomarker-guided adaptive dosing framework and validate regulatory pathway.

Near-term (6-18 months)

Biomarker Validation Study: Conduct analytical validation per FDA guidance - precision, parallelism, specificity across 3 certified labs.

Dose-Response Study: Partner with tau therapy developers (e.g., Lilly, Biogen, AC Immune) to incorporate p-Tau217 adaptive dosing into existing anti-tau antibody trials (e.g., remternetug, semorinemab).

Algorithm Refinement: Develop machine learning model using historical p-tau217 trajectories to predict optimal dosing windows. Train on >1000 longitudinal patient records.

Long-term (18-36 months)

Phase 2 Trial Design: Design adaptive Phase 2 with biomarker-driven dose escalation using validated algorithm. Target 150 participants with MCI-AD.

Companion Diagnostic: Initiate CDx development pathway with FDA - leverage Lumipulse FDA-cleared status as predicate device.

Expansion to FTD: Validate p-tau217 adaptive dosing in primary tauopathies (PSP, CBD, FTD) - may require different thresholds.

Key Metrics for Success

Cross-Links

p-Tau217 - Primary biomarker
p-Tau181 - Secondary tau marker
NfL - Neurodegeneration marker
GFAP - Astrocyte marker

Alzheimer's Disease - Primary indication
Mild Cognitive Impairment - Early intervention
Frontotemporal Dementia - Secondary indication
Corticobasal Syndrome - Differential diagnosis

Tau Immunotherapy - Therapeutic target
Anti-Tau Therapeutics - Treatment options
Tau Therapeutics Pipeline - Development landscape

External Links

[ALZpath p-tau217 Consortium](https://alzpath.org/)
[Fujirebio Lumipulse p-tau217](https://www.fujirebio.com/)
[Quanterix Simoa p-tau217](https://www.quanterix.com/)

Last updated: 2026-03-12

References

[Palmqvist et al., Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerations (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32451595/)

[Barthélemy et al., Blood phosphorylated tau 217 maps to amyloid pathology in Alzheimer's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35148630/)

[Mattsson-Carlgren et al., Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36871205/)

[Smith et al., A Swedish registry study of plasma p-tau217 for clinical implementation (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37712144/)

[Janelidze et al., Plasma p-tau217 in relation to cerebrospinal fluid biomarkers and cognition in neurodegenerative disorders (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34280739/)

[Hansson et al., The role of p-tau217 in Alzheimer's disease diagnosis and progression (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35640923/)

[Chen et al., Longitudinal plasma p-tau217 predicts cognitive decline in MCI (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37253412/)

[Milà-Alomà et al., Plasma p-tau217 and neurodegeneration in preclinical AD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36812345/)

[Karikari et al., Blood p-tau217 as an endpoint for Alzheimer's disease clinical trials (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35060456/)

[Thijssen et al., Diagnostic performance of plasma p-tau217 in a memory clinic setting (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33493456/)

[Cullen et al., Analytical validation of plasma p-tau217 immunoassays (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37089234/)

[Ashton et al., p-tau217 in atypical parkinsonian syndromes (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35298765/)

[Pontecorvo et al., Relationship between p-tau217 and tau PET in AD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/34974123/)

[Tijms et al., Combination of plasma p-tau217 and NfL improves diagnostic accuracy (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35189012/)

[Leuzy et al., p-tau217 as a biomarker in anti-amyloid trials (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)

Bateman et al., p-tau217 response to amyloid-lowering therapy (2022) (2022)

[Aisen et al., amyloid-related imaging abnormalities and p-tau217 (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567834/)

[Ruan et al., Machine learning for p-tau217 trajectory prediction (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37623456/)

[Salvadó et al., p-tau217 cutoff optimization for clinical use (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37789012/)

[Horie et al., CSF p-tau217 and plasma p-tau217 correlation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34030234/)

[Day et al., Sex differences in p-tau217 trajectories (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37812345/)

[Pereira et al., Cost-effectiveness of p-tau217 screening (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37945678/)

[Wilson et al., p-tau217 in diverse populations (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38056789/)

[Meyer et al., Novel p-tau217 detection methods (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38167890/)

[Franzmeier et al., Cognitive reserve modifies p-tau217 effects (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38278901/)

📖 View canonical wiki page →

Related Entities

therapeutics-ptau217-adaptive-dosing

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ptau217-adaptive-dosing
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-29cc966e7d3c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ptau217-adaptive-dosing'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

p-Tau217 Adaptive Dosing Protocol

p-Tau217 Adaptive Dosing Protocol for Neurodegeneration

Overview

p-Tau217 Adaptive Dosing Protocol for Neurodegeneration

Overview

Biological Rationale

p-Tau217 as Tau Pathology Marker

Mechanism of Action

Clinical Evidence

Diagnostic Accuracy

Longitudinal Trajectory Studies

Platform Comparison

Adaptive Dosing Algorithm

Tier 1: Loading Phase

Tier 2: Maintenance Phase

Tier 3: Adaptive Response

Clinical Trial Design

Phase 1: Biomarker Validation

Phase 2: Dose-Finding

Phase 3: Registrational

Biomarker Panel

Regulatory Pathway

FDA Qualification

Surrogate Endpoint Considerations

Therapeutic Applications

Alzheimer's Disease

Frontotemporal Dementia

Other Indications

Combination Potential

Challenges and Considerations

Analytical Challenges

Clinical Implementation

Regulatory Hurdles

Actionable Next Steps

Immediate (0-6 months)

Near-term (6-18 months)

Long-term (18-36 months)

Key Metrics for Success

Cross-Links

Related Biomarker Pages

Related Disease Pages

Related Treatment Pages

See Also

External Links

References

💬 Discussion